AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +29.41%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.15, delivering a surprise of +11.76%. Over the last four quarters, the compa ...